Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s606, 2025. DOI: 10.25251/yhn4cs07. Disponível em: https://skin.dermsquared.com/skin/article/view/3881. Acesso em: 20 apr. 2026.